Veeva Vault CDMS Selected for Enterprise-wide Deployment
Veeva Systems announced that a top 20 pharmaceutical company has selected Veeva Vault Clinical Data Management System (CDMS) as their global standard for EDC, coding, data cleaning, and reporting.
“This is a landmark announcement for the clinical data management market,” said Henry Levy, general manager, Veeva Vault CDMS. “Veeva Vault CDMS was selected because the company wanted a modern cloud solution on a world-class platform from a partner they could trust.”
Vault CDMS provides a suite of clinical data management applications that combines coding, EDC, data cleaning, and reporting all on a single cloud platform. Companies can now manage study build through execution in an integrated way. With a complete and concurrent view of their data, clinical development teams can make better decisions.
As part of Vault CDMS, Veeva Vault EDC provides an intuitive interface for capturing clinical trial data. Designed for flexibility, Vault EDC allows customers to run complex multi-arm adaptive trials and make mid-study amendments without downtime or migrations.
“Our goal is to become the market leader in the clinical data management market over time through innovation and product excellence,” added Levy. “We are honored to partner with this important customer and look forward to delivering customer success for many years.”
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
